Home » Stocks » ADXS

Advaxis, Inc. (ADXS)

Stock Price: $0.415 USD -0.031 (-6.95%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Pre-market: $0.414 -0.001 (-0.17%) May 11, 7:22 AM
Market Cap 57.81M
Revenue (ttm) 1.87M
Net Income (ttm) -22.59M
Shares Out 83.94M
EPS (ttm) -0.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $0.415
Previous Close $0.446
Change ($) -0.031
Change (%) -6.95%
Day's Open 0.453
Day's Range 0.411 - 0.455
Day's Volume 5,524,273
52-Week Range 0.264 - 1.570

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PRINCETON, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today...

1 week ago - GlobeNewsWire

Non-dilutive capital will support advancement of ADXS-HOT neoantigen program Non-dilutive capital will support advancement of ADXS-HOT neoantigen program

2 weeks ago - GlobeNewsWire

Non-dilutive capital to support advancement of ADXS-HOT neoantigen program Non-dilutive capital to support advancement of ADXS-HOT neoantigen program

2 weeks ago - GlobeNewsWire

Advaxis, Inc. (NASDAQ: ADXS), CEO Ken Berlin presented at the Benzinga Biotech Small-Cap Conference on March 24, 2021. Advaxis, Inc., a clinical-stage biotechnology company focused on the development an...

2 weeks ago - Benzinga

PRINCETON, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy...

4 weeks ago - GlobeNewsWire

Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a pharmacodynamic biomarker in T cells during PD-1 blockade

1 month ago - GlobeNewsWire

PRINCETON, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and P...

1 month ago - GlobeNewsWire

Enrolling strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and/or restore sensitivity to checkpoint inhibitors

3 months ago - GlobeNewsWire

Non-dilutive capital strengthens balance sheet to further advance ADXS-HOT neoantigen program Non-dilutive capital strengthens balance sheet to further advance ADXS-HOT neoantigen program

3 months ago - GlobeNewsWire

PRINCETON, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today ...

4 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - December 16, 2020) - Levi & Korsinsky announces it has commenced an investigation of Advaxis, Inc. (NASDAQ: ADXS) concerning possible breaches of fiduciary duty. To...

4 months ago - Newsfile Corp

PRINCETON, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy ...

5 months ago - GlobeNewsWire

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and analyze their ...

5 months ago - Insider Monkey

Alnylam Pharmaceuticals (NASDAQ: ALNY) shares are trading higher on Tuesday after the company announced its OXLUMO injection has received FDA approval for the treatment of primary hyperoxaluria type 1 t...

Other stocks mentioned: ALNY, ARWR
5 months ago - Benzinga

PRINCETON, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy ...

5 months ago - GlobeNewsWire

PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy ...

5 months ago - GlobeNewsWire

Disease control rate of 67% and overall response rate of 17% in first six evaluable patients with immediate prior progression on KEYTRUDA ®

6 months ago - GlobeNewsWire

PRINCETON, N.J., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Advaxis , Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today...

6 months ago - GlobeNewsWire

PRINCETON, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, tod...

7 months ago - GlobeNewsWire

Strategic transition to Investigator sponsored IND from previously announced Advaxis sponsored IND

7 months ago - GlobeNewsWire

Strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and or restore sensitivity to checkpoint inhibitors

8 months ago - GlobeNewsWire

PRINCETON, N.J., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products toda...

8 months ago - GlobeNewsWire

PRINCETON, N.J., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, toda...

8 months ago - GlobeNewsWire

PRINCETON, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today...

9 months ago - GlobeNewsWire

PRINCETON, N.J., June 23, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, toda...

10 months ago - GlobeNewsWire

Advaxis, Inc. (ADXS) CEO Ken Berlin on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Expanding Phase 1/2 Study of ADXS-503 in NSCLC based on sustained and durable clinical responses in first two patients from Part B combination arm with KEYTRUDA®

10 months ago - GlobeNewsWire

Sustained clinical benefit seen in patients treated with ADXS-503 in combination with KEYTRUDA® after 16 weeks, including a partial response and stable disease in patients who had most recently progress...

11 months ago - GlobeNewsWire

Advaxis Is One Biotech That Should Be On Your Radar; Targeting Large NSCLC And Prostate Cancer Drug Markets

1 year ago - Seeking Alpha

First two patients treated in the combination arm who previously progressed on KEYTRUDA® showed substantial tumor shrinkage with ADXS-503 treatment in combination with KEYTRUDA®

1 year ago - GlobeNewsWire

PRINCETON, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherap...

1 year ago - GlobeNewsWire

Advaxis, Inc. (ADXS) CEO Kenneth Berlin on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Nanocap Advaxis, Inc. is seeing strength Wednesday following an announcement concerning its cervical cancer drug.

1 year ago - Benzinga

Advaxis (ADXS) closed the most recent trading day at $3.29, moving -0.3% from the previous trading session.

2 years ago - Zacks Investment Research

Is (ADXS) Outperforming Other Medical Stocks This Year?

2 years ago - Zacks Investment Research

Equity offerings played a big role for two of these companies.

2 years ago - The Motley Fool

Here's a roundup of top developments in the biotech space over the last 24 hours.

Other stocks mentioned: ADMA, NVS, RHHBY
2 years ago - Benzinga

Shares of Advaxis Inc. plummeted 25% to pace all premarket declines Wednesday, after the biotechnology company's public offering of shares priced at a deep discount.

2 years ago - Market Watch

The small-cap biotech reported encouraging news about its prostate cancer therapy.

2 years ago - The Motley Fool

Advaxis, Inc. has announced a reverse stock split and clinical trial updates at the American Association of Cancer Research annual meeting in recent days.

2 years ago - Benzinga

As of late, it has definitely been a great time to be an investor in Advaxis.

2 years ago - Zacks Investment Research

This owner and operator of a late-stage biotechnology company has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 64.7% over the last 60 ...

2 years ago - Zacks Investment Research

Is (ADXS) Outperforming Other Medical Stocks This Year?

2 years ago - Zacks Investment Research

About ADXS

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunothe... [Read more...]

Industry
Biotechnology
Founded
2002
CEO
Kenneth Berlin
Employees
17
Stock Exchange
NASDAQ
Ticker Symbol
ADXS
Full Company Profile

Financial Performance

In 2020, Advaxis's revenue was $253,000, a decrease of -98.79% compared to the previous year's $20.88 million. Losses were -$26.47 million, 59.3% more than in 2019.

Financial Statements